|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Background Olfactory cortexes and the olfactory tracts are involved in sporadic Creutzfeldt–Jakob disease. We examined peripheral regions of the olfactory sensory pathway, including the olfactory mucosa, to assess whether pathologic infectious prion protein (PrPSc) is deposited in the epithelium lining the nasal cavity.
Methods We studied nine patients with neuropathologically confirmed sporadic Creutzfeldt–Jakob disease. We obtained the brain, the cribriform plate with the attached olfactory mucosa, and the surrounding respiratory epithelium at autopsy. Control samples of nasal mucosa were obtained post mortem or at biopsy from age-matched control subjects and from control patients with other neurodegenerative diseases. The olfactory and respiratory mucosa and the intracranial olfactory system were analyzed by light microscopy, immunohistochemistry, and Western blotting for pathological changes and for deposition of PrPSc.
Results In all nine patients with sporadic Creutzfeldt–Jakob disease, PrPSc was found in the olfactory cilia and central olfactory pathway but not in the respiratory mucosa. No PrPSc was detected in any of the tissue samples from the 11 controls.
Conclusions Our pathological and biochemical studies show that PrPSc is deposited in the neuroepithelium of the olfactory mucosa in patients with sporadic Creutzfeldt–Jakob disease, indicating that olfactory biopsy may provide diagnostic information in living patients. The olfactory pathway may represent a route of infection and a means of spreading prions.
Currently, there are no peripheral markers of sporadic Creutzfeldt–Jakob disease for use in the diagnosis of the disease in living patients. Definitive diagnosis requires pathological examination of the brain and the detection of the abnormal PrP isoform by immunohistochemical analysis or immunoblotting.10 Attention has recently been devoted to the biochemical analysis of components of the eye and optic nerve in sporadic Creutzfeldt–Jakob disease,11 but little attention has been paid to the olfactory sensory pathway.
We have evidence that the olfactory tracts and cortexes are frequently involved in sporadic Creutzfeldt–Jakob disease, regardless of the genotype at polymorphic codon 129 of PRNP and the physicochemical properties of PrPSc. We sought to determine whether patients with sporadic disease had detectable levels of PrPSc or deposits of abnormal PrP in the neuroepithelium of the nasal cavity.
Methods
Patients
We studied nine patients who had been given a diagnosis of definite sporadic Creutzfeldt–Jakob disease on the basis of neuropathological findings and the detection of PrPSc in the brain on immunohistochemical analysis and Western blotting.10,12,13 We obtained postmortem specimens from the patients between February 2000 and March 2002, after being notified by their treating physicians in the Veneto region of Italy. Cerebrospinal fluid samples were obtained from all patients, and each sample was tested for 14-3-3 protein.14 All electroencephalographic tracings were evaluated with the use of standardized criteria.15
At the time of notification and during follow-up, the patients were classified according to established diagnostic criteria.12,16 Probable sporadic Creutzfeldt–Jakob disease was diagnosed in patients who had progressive dementia of less than two years' duration, complexes of periodic sharp and slow waves on the electroencephalogram, and at least two of the following clinical features: myoclonus, visual or cerebellar symptoms (or both), pyramidal or extrapyramidal signs (or both), and akinetic mutism. Patients who fulfilled the clinical criteria but who did not have complexes of periodic sharp and slow waves were classified as having possible sporadic Creutzfeldt–Jakob disease. The duration of the disease was calculated from the onset of neurologic symptoms or signs to death.
Determination of the PRNP Genotype
After obtaining written informed consent from the patients' next of kin, we extracted genomic DNA from frozen brain tissues and sequenced the entire coding region of PRNP, as described elsewhere.17
Tissue Collection and Processing
The cribriform plate and the upper portion of the nasal septum, with the attached olfactory mucosa (Figure 1), were obtained at autopsy from the nine patients with sporadic Creutzfeldt–Jakob disease, five age-matched control subjects without a neurologic disorder, three patients with Alzheimer's disease, two patients with vascular dementia, and one patient with corticobasal degeneration. In all subjects, the interval between death and autopsy ranged from 12 to 32 hours. In each subject, the olfactory mucosa on each side of the nose, easily recognizable because of its yellowish color, was divided in two. One piece was fixed in 4 percent buffered formaldehyde solution and treated for 20 minutes with formic acid — a process that denatures amyloid-protein aggregates and enhances their antigenicity18 — before being embedded in paraffin for neuropathological examination and immunohistochemical analysis. The other piece was frozen and stored at –80°C for up to one month until biochemical analyses could be performed. The respiratory mucosa, obtained from contiguous regions of the turbinates, was processed in the same manner. The left olfactory bulb and tract, together with the ipsilateral prepiriform cortex (including the lateral olfactory gyrus and the olfactory uncal region) and the periamygdaloid and entorhinal cortexes, were fixed for neuropathological examination. Contralateral areas were frozen and stored at –80°C until biochemical analyses could be performed. In addition, the optic nerve, frontal, temporal, parietal, and occipital cortexes, hippocampus, thalamus, striatum, and cerebellum were obtained for both pathological and biochemical studies. Specimens obtained for pathological examination were pretreated with formic acid for one hour before being embedded in paraffin.
|
Immunocytochemical Analysis
Ten paraffin sections that were 8 µm thick were obtained from each sample of olfactory mucosa and other tissues. Sections were deparaffinized, rehydrated, treated with 98 percent formic acid for 20 minutes at room temperature, and autoclaved at 121°C for 10 minutes in 1.5 mM hydrochloric acid. Sections were rinsed and then incubated overnight at 4°C with monoclonal antibody 3F4 (1:500 dilution), which recognizes nonhuman prion protein and the human prion protein residues 109 to 112.21 The mouse monoclonal antibody LB509 (1:500 dilution, Zymed Laboratories), which recognizes 
-synuclein, expressed by olfactory receptor neurons and basal cells of the olfactory mucosa,22 was used for the unequivocal identification of these cells when necessary. Subsequent antibody detection involved incubation with a biotinylated goat antimouse secondary antibody for one hour (1:500 dilution, Vector Laboratories) at room temperature, followed by incubation with the avidin–biotin–peroxidase complex (Vectastain ABC-Elite kit, Vector Laboratories) according to the manufacturer's instructions. The samples were then stained with 0.06 percent 3,3'-diaminobenzidine as the chromogen and 0.006 percent hydrogen peroxide in 50 mM TRIS buffer, pH 7.6.
Immunoblot Analysis
From each sample of central nervous system tissue, 100 mg of tissue was homogenized in 0.9 ml of lysis buffer (100 mM sodium chloride, 10 mM EDTA, 0.5 percent nonaethyleneglycol octylphenyl ether, 0.5 percent sodium deoxycholate, and 10 mM TRIS, pH 7.4). For olfactory or respiratory mucosa, each sample of 100 mg of tissue was homogenized in 0.4 ml of lysis buffer. Aliquots were adjusted to a final concentration of 20 or 100 µg of proteinase K (Boehringer Mannheim) per milliliter and incubated at 37°C for 10 to 60 minutes. Samples, equivalent to 300 µg of wet tissue, were resolved on 12 percent gels for sodium dodecyl sulfate–polyacrylamide-gel electrophoresis and then transferred onto polyvinylidene difluoride membrane (Immobilon P, Millipore) for two hours at 60 V. Membranes were blocked with 1 percent nonfat dry milk in 10 mM TRIS, 150 mM sodium chloride, and 0.1 percent Tween-20, pH 7.5, for one hour at 37°C and incubated overnight at 4°C with monoclonal antibody 3F4 (1:10,000 dilution). Blots were developed with an enhanced chemiluminescence system (ECL, Amersham Pharmacia Biotech) and visualized on an autoradiography film (Hyperfilm, Amersham Pharmacia Biotech). Films were scanned with a densitometer (model GS-710, Biorad). The relative amounts of PrPC expressed or PrPSc distributed were calculated as previously described.23
To enhance the detection of PrPSc, samples of the olfactory and respiratory mucosa were also prepared according to the procedure of Wadsworth et al.11 Briefly, 100 mg of wet tissue was homogenized in 0.9 ml of 2 percent sarkosyl in phosphate-buffered saline, pH 7.4. Cellular debris was removed by centrifugation at 1000 rpm for 2 minutes, and samples were incubated for 30 minutes at 37°C with constant agitation in phosphate-buffered saline containing 50 U of Benzonase (Benzon nuclease, Merck) per milliliter and 1 mmol of magnesium chloride per liter. Subsequently, samples were adjusted to 0.3 percent sodium phosphotungstic acid (final concentration), incubated at 37°C for 30 minutes, and centrifuged at 14,000 rpm for 30 minutes. The supernatant was saved, and the pellet was dissolved in 20 µl of phosphate-buffered saline, pH 7.4, containing 0.1 percent sarkosyl. The supernatant and the pellet were adjusted to a final concentration of 20 µg of proteinase K per milliliter and incubated at 37°C for 30 minutes.
Results
Clinical Findings, PrPSc Typing, and Codon 129 Genotyping
The age, sex, clinical data, results of electroencephalography and tests for 14-3-3 protein in the cerebrospinal fluid, PrPSc type, and PRNP codon 129 polymorphism of each patient with sporadic Creutzfeldt–Jakob disease are reported in Table 1. In the final stages of the disease, all the patients had dementia with at least two of the diagnostic criteria for sporadic Creutzfeldt–Jakob disease,12,16 except Patient 1, who rapidly lapsed into akinetic mutism. Patients with complexes of periodic sharp and slow waves on the electroencephalogram were given a clinical diagnosis of probable sporadic Creutzfeldt–Jakob disease, whereas patients without typical electroencephalographic changes were classified as having possible sporadic Creutzfeldt–Jakob disease. None of the patients had a pathogenic mutation in the coding region of PRNP.
|
Light microscopy was used to confirm the identity of the olfactory and respiratory mucosa on the basis of histologic criteria.24 In selected specimens, examined in a blinded fashion, the expression of -synuclein was used to confirm that the olfactory epithelium and the respiratory epithelium had been properly identified. This protein is abundant in the cytoplasm and dendrites of olfactory receptor neurons and absent in ciliated columnar epithelial cells of the respiratory epithelium. Staining with hematoxylin and eosin of sections of the olfactory mucosa from patients with sporadic Creutzfeldt–Jakob disease did not reveal major pathological changes, as compared with corresponding tissues from controls with and those without other neurodegenerative disorders. Immunostaining for PrP was negative in the olfactory epithelium of all postmortem and biopsy specimens from controls (Figure 2A). In contrast, immunohistochemical analysis revealed marked deposition of PrP in the cilia of olfactory receptor neurons and a faint PrP immunoreactivity in basal cells of the olfactory epithelium from all patients with sporadic Creutzfeldt–Jakob disease (Figure 2B and Figure 2C). Conversely, the respiratory epithelium did not stain for PrP (data not shown). In the brains of patients with sporadic Creutzfeldt–Jakob disease, there was selective deposition of PrP in olfactory-bulb glomeruli (Figure 2D), olfactory tracts (Figure 2E), and primary olfactory cortexes (Figure 2F).
|
Western blot analysis of samples of olfactory and respiratory mucosa from controls showed that both tissues constitutively expressed PrPC. PrPC was detected mainly in a highly glycosylated form and had a slightly faster rate of migration than that derived from the brain (Figure 3). The levels of PrPC expression in the olfactory and respiratory mucosa were approximately 20 percent and 13 percent, respectively, of that in brain.
|
After treatment with proteinase K at a concentration of 20 µg per milliliter for 20 or 10 minutes, PrPSc was undetectable on immunoblot analysis of homogenates of olfactory and respiratory mucosa from patients with sporadic Creutzfeldt–Jakob disease and from controls (Figure 4A). To increase the sensitivity of the method of PrPSc detection, we tested the ability of sodium phosphotungstic acid, which binds efficiently to hamster and human PrPSc,11,25 to precipitate PrPSc from the nasal mucosa of patients with sporadic Creutzfeldt–Jakob disease. Western blot examination of the supernatant from homogenates of olfactory mucosa showed a major PrP band migrating at approximately 33 kD, which was digested by proteinase K (Figure 4B, lanes 1 and 2). By contrast, Western blot examination of the insoluble fraction, recovered in the pellet, showed four main PrP-reactive bands in the range of approximately 23 to 35 kD. Treatment of the insoluble fraction with proteinase K generated three major proteinase K–resistant PrPSc bands (Figure 4B, lanes 3 and 4), with an unglycosylated fragment of approximately 22 kD in all patients who were homozygous for methionine and of approximately 21 kD in the patient who was homozygous for valine at codon 129. In four patients, the olfactory mucosa contained levels of PrPSc equivalent to approximately 3 percent of those found in the olfactory-bulb homogenates. PrPSc immunoreactivity was not detected either in the respiratory mucosa from patients with sporadic Creutzfeldt–Jakob disease or in the olfactory and respiratory mucosa from control subjects.
|
After treatment with proteinase K at a concentration of 100 µg per milliliter for one hour, patients who were homozygous for methionine had the largest amounts of PrPSc in the neocortex, as expected, with smaller amounts in the thalamus, basal ganglia, and cerebellum (Figure 5A). The amount of PrPSc was very low in the hippocampus, whereas the entorhinal and olfactory cortexes had relatively large quantities of PrPSc. In addition, in all nine patients, PrPSc was detected in the olfactory bulb and tract. The protein was undetectable in samples from the prechiasmatic optic nerve.
|
Discussion
We found that in patients with sporadic Creutzfeldt–Jakob disease, pathologic prion protein is selectively deposited within the neuroepithelium of the olfactory mucosa, although cellular prion protein is evenly distributed in both the olfactory and respiratory mucosa. These results indicate that factors other than constitutive expression of PrPC determine whether PrP is deposited at the level of the olfactory cilia but not at the level of the respiratory cilia. Our findings, as well as our own unpublished observations, provide evidence that the olfactory sensory pathway is involved in sporadic Creutzfeldt–Jakob disease.
The detection of PrPSc on immunocytochemical analysis and Western blotting is important for the diagnosis of prion diseases.26 PrPSc is an accurate marker for the infectious agent, and its presence suggests infectivity. The relatively low level of PrPSc that we detected in the olfactory mucosa of patients with sporadic Creutzfeldt–Jakob disease (about 3 percent of that in the olfactory bulb) may be related to the characteristics of the olfactory epithelium. The main factors that may limit the accumulation of PrPSc in the olfactory epithelium are the low level of constitutive expression of PrPC, as compared with that in brain tissues, and the short life span (a few weeks) of the olfactory receptor neurons, which are continually expelled in the upper nasal cavity as they are replaced by basal neurons. The highly selective deposition of PrPSc in olfactory receptor neurons may indicate affinity mechanisms or interactions with one or more of the thousands of receptor proteins expressed in the apical portion of the cilia.27
Besides providing evidence of the deposition of PrPSc in the peripheral tissues of patients with sporadic Creutzfeldt–Jakob disease, our data have important implications regarding both the in vivo diagnosis of the condition and the risk of infection from living patients. Since we examined postmortem samples of olfactory mucosa, we could not pinpoint the stage at which PrPSc deposition occurs in sporadic Creutzfeldt–Jakob disease. However, the detection of PrPSc in olfactory tissue in patients with disease of short duration suggests that the PrPC may be converted to PrPSc at the same time as it is in the central nervous system, where the formation of PrPSc always precedes the appearance of lesions.28 In one patient the disease presented with anosmia, and there is a report of variant Creutzfeldt–Jakob disease presenting with loss of taste and smell.29 In the patient with the ataxic variant of relatively short duration, PrPSc accumulated in the olfactory paleocortex, despite the absence of accumulation in the hippocampus and neocortex. Given the small number of patients analyzed in this study, our results should be viewed with caution, but taken together they suggest that the olfactory system is involved at an early stage in sporadic Creutzfeldt–Jakob disease. In contrast, the retina and optic nerves do not have PrPSc deposition,11 though the retina may be vulnerable.30 Our findings suggest that a biopsy of olfactory tissue in patients with suspected sporadic Creutzfeldt–Jakob disease may provide a means of early clinical diagnosis and a way to assess the potential effectiveness of anti-prion compounds when they become available.31
The presence of PrPSc in the nasal cavity of patients with sporadic Creutzfeldt–Jakob disease also raises the question of whether these patients represent a source of infection or have been infected through the olfactory route. Human prion diseases can be transmitted through contaminated electrodes and neurosurgical instruments,5 and recent work demonstrates that prions are easily and tightly bound by stainless-steel surfaces.32 Following the appearance of variant Creutzfeldt–Jakob disease, which is caused by the same prion strain as that responsible for cattle bovine spongiform encephalopathy,33 and the demonstration of infectious prion protein in human tonsillar tissues,34 precautions to avoid iatrogenic transmission have been undertaken in the United Kingdom. Similarly, the demonstration of a rather high level of infectivity in gingival and dental-pulp tissues from hamsters with experimentally induced scrapie has aroused concern about the risk of transmission in humans through dental work.35 Our findings also call attention to the possibility that endoscopic and surgical procedures involving the upper vault of the nasal cavity represent a risk factor for prion spreading. However, we know of no cases of disease transmission by this route.
It remains unknown whether the olfactory epithelium represents a gate of entry or only a site of infection during the propagation of prions in neural circuits. In the light of our findings, the hypothesis that sporadic Creutzfeldt–Jakob disease might be initiated by somatic mutations in PRNP36 is intriguing. It should be emphasized that neither the basal epithelium of the olfactory mucosa nor the olfactory bulb is a postmitotic tissue; instead they represent well-established sites of ongoing peripheral and central neurogenesis.37 Thus, if sporadic Creutzfeldt–Jakob disease is caused by somatic mutations of PRNP in the neurons of adults, then the olfactory epithelium and the olfactory bulb are candidate sites for such events.
Supported by a grant from the Ministero della Ricerca Scientifica e Tecnologica, Progetto Strategico Neuroscienze (01.00455.ST97, to Dr. Monaco).
We are indebted to Massimo Tabaton, M.D. (University of Genoa, Genoa, Italy), for providing olfactory-biopsy specimens from patients with neurodegenerative disorders; to Gianfranco Marchiori, M.D. (Treviso), Alessio Dalla Libera, M.D. (Thiene), Tiziana Rosso, M.D. (Arzignano, Vicenza), Paolo Liberini, M.D. (Brescia), and Nicola Carraro, M.D. (Trieste), for assistance and follow-up of patients; to Daniela Danieli, M.D. (Vicenza), Rossana Bussani, M.D. (Trieste), Giuseppe Sacchi, M.D. (San Donà), Romano Colombari, M.D. (Arzignano), and Gianmario Mariuzzi, M.D. (Verona), for help in providing pathological specimens; and to Giuseppe Bertini, M.D. (University of Verona, Verona), for the original drawing of Figure 1.
Source Information
From the Departments of Neurologic and Visual Sciences (G.Z., S.F., M. Gelati, M.F., A.F., T.C., N.R., S.M.), Ear, Nose, and Throat (P.Z.), Morphologic and Biomedical Sciences (M.B.), and Agricultural and Industrial Biotechnologies (P.G.R.), Section of Clinical Neurology, University of Verona, Verona; the Laboratory of Virology, Istituto Superiore di Sanità, Rome (F.C., M.P.); and the Department of Pathology, University of Padua, Padua (M. Gardiman) — all in Italy.
Address reprint requests to Dr. Monaco at the Section of Clinical Neurology, Department of Neurologic and Visual Sciences, Policlinico G.B. Rossi, Piazzale L.A. Scuro 10, 37134 Verona, Italy, or at salvatore.monaco{at}mail.univr.it.
References
-, 
-, and 
-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases. Exp Neurol 1999;160:515-522. [CrossRef][ISI][Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |
Previous
